The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

But decades later, the market for kids’ art supplies has a whole lot more to offer. So to help me (and you) pick a gift for a friend’s third-grader, prepare for a toddler’s first foray into ...

But what is “high-end fitness equipment” anyway? Essentially, we’re talking about luxury, all-in-one workout stations that can fit in most houses or apartments. This could take the form of a ...

Investing.com -- Goldman Sachs initiated coverage on ResMed Inc (NYSE ... strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...

The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

VGM Group has acquired SleepGlad, a secure, 3D mask-fitting platform for CPAP and non-invasive ventilators, from Baxter ...